Latest Industry Insights

While the healthcare community has rallied together in efforts to develop therapeutics and vaccines for COVID-19, we must not forget the other trials underway and those in the R&D pipeline that will also help conquer disease. There is an urgent need to use advanced and innovative approaches to ensure the continuity of existing trials and the start of new studies.

In this interview we focus on Research-Aid Networks' activities in relation to the COVID-19 pandemic. Research-Aid Networks' Matthew Badham, highlights the importance of collaboration and communication in these unprecedented times, discusses what we currently know about the novel coronavirus (SARS-CoV-2) and elaborates on the analysis RAN has been conducting.

A consortium led by the Jenner Institute at Oxford University is working to rapidly develop, scale-up and manufacture the potential COVID-19 vaccine, ChAdOx1 nCov-19, or ChAdOx1, for fast-tracked clinical trials. Technology Networks spoke with Tony Hitchcock, Technical Director at Cobra Biologics to find out more about the consortium's aims, how the vaccine works and to gain insights on realistic timelines for vaccine development and manufacturing.

Technology Networks recently spoke with Martin Butzal, Head of Medical Europe at bluebird bio, to learn more about the exciting developments and key trends in the gene therapy space.

Technology Networks spoke with David Chang, MD, PhD, President, Chief Executive Officer and Co-Founder of Allogene to learn about the recent developments in the fast-developing allogeneic cell therapy research space and Allogene's visions for the future.

Technology Networks recently spoke with Joe Foster, COO, Mogrify, to learn about the biotech company's proprietary platform, the challenges encountered in developing cell therapies and to gain Mogrify's insights on the future of this exciting research space.

Technology Networks recently spoke with three of the leaders in the cell and gene therapy space, Allogene Therapeutics, bluebird Bio and Mogrify to gain their insights on the next developments in this space.

Technology Networks recently spoke with Gary Kruppa, PhD, Vice President of Proteomics, Bruker Daltonics Inc., to learn more about the advancing research area immunopeptidomics, and to discuss the current status of single cell proteomics.

Sorrento Therapeutics Inc. and SmartPharm Therapeutics Inc. recently announced a research and development collaboration in which they will work to develop a next-generation, gene-encoded antibody vaccine for COVID-19. Technology Networks spoke with SmartPharm's CEO Jose Trevejo to learn more about the collaboration and the next steps in the development of the vaccine.

Vaccine development is a science over 200 years in the making, but creating a preventative that is effective and safe remains a complex and challenging task. Among the many companies working to create a vaccine for COVID-19 is Tonix Pharmaceuticals. Their pre-clinical candidate vaccine uses a unique platform that sets it apart from other efforts to fight the pandemic. We spoke to Tonix CEO Seth Lederman to find out more.